News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 157–168 of 243 stories

Sterling Pharma Solutions Doubles Capacity at Deeside ADC Facility

Sterling Pharma Solutions has completed an expansion of its Deeside facility that doubles its manufacturing capacity, adding a 500-litre reactor and a new GMP suite with a 1,400 sq ft Grade C cleanroom. A new 3,400 sq ft analytical laboratory with expanded HPLC/UPLC capacity supports the site, which can handle compounds down to OEB 5 exposure limits.

Mironid Doses First Cohorts in Phase 1 Trial of LoAc Candidate for ADPKD

Mironid has dosed the initial cohorts in its Phase 1 trial of its first-in-class LoAc small molecule for Autosomal Dominant Polycystic Kidney Disease, marking its transition to a clinical-stage company. The dose-escalation study in healthy volunteers is evaluating safety, tolerability and pharmacokinetics, with its single ascending dose part designed to enrol up to 48 participants across six cohorts.

Rezera Reports Phase 1 Results for Brain-Penetrant NLRP3 Inhibitor Trabzanoflast

Rezera, the company formerly known as NodThera, has reported topline Phase 1 results for trabzanoflast, its oral, brain-penetrant NLRP3 inhibitor for neuroinflammatory diseases, showing the drug was generally well tolerated in healthy volunteers. Continuous cerebrospinal fluid sampling confirmed high central nervous system exposure, and the company said the results support continued clinical development.

Tangram Therapeutics Appoints Dr Laura Roca-Alonso as CEO and Board Director

Tangram Therapeutics has appointed Dr Laura Roca-Alonso as Chief Executive Officer and Executive Director of the Board, confirming her in the role after serving as Interim CEO since March 2026. Roca-Alonso, Chief Operating and Business Officer since 2020, will lead the company as it works towards clinical data on its co-lead RNAi programmes, TGM-312 for MASH and TGM-148 for bleeding disorders, over the next 12 months.